Abstract Number: 2944 • 2015 ACR/ARHP Annual Meeting
Presepsin (sCD14 subtype) Concentration Is Elevated and Reflects Disease Activity in Systemic Lupus Erythematous Patients
Background/Purpose: Presepsin (sCD14 subtype) has recently been identified as a novel biomarker for predicting sepsis. Because presepsin is produced as a consequence of cellular phagocytosis,…Abstract Number: 2945 • 2015 ACR/ARHP Annual Meeting
Diffuse Alveolar Hemorrhage in SLE: Risk Factors, Response to Therapy, and Survival
Background/Purpose: While diffuse alveolar hemorrhage (DAH) is recognized as a life-threatening complication of SLE, little is known about its risk factors and response to therapy. …Abstract Number: 2946 • 2015 ACR/ARHP Annual Meeting
Mortality Among SLE Patients in the National Data Bank for Rheumatic Diseases
Background/Purpose: To investigate risk of mortality among SLE patients cohort in the NDB.Methods: Systemic lupus erythematous (SLE) and non-inflammatory rheumatic disease (NIRD) patients were studied…Abstract Number: 2947 • 2015 ACR/ARHP Annual Meeting
Association of Anti-NR2 and U1RNP Antibodies with Neurotoxic Inflammatory Mediators in Cerebrospinal Fluid from Patients with Neuropsychiatric Systemic Lupus Erythematosus
Background/Purpose: Autoantibodies (auto Abs) in cerebrospinal fluid (CSF) and inflammatory mediators (IMs) may be involved in the pathogenesis of neuropsychiatric systemic lupus erythematosus (NPSLE). Previous…Abstract Number: 2948 • 2015 ACR/ARHP Annual Meeting
How Do Patients with Newly Diagnosed SLE Present? a Multicenter Cohort Analysis to Inform the Development of New Classification Criteria for SLE
Background/Purpose: SLE onset may be insidious with clinically evident disease developing over years. Current SLE classification criteria may not classify patients with early SLE well.…Abstract Number: 2949 • 2015 ACR/ARHP Annual Meeting
Differential Serum Cytokine Profile in Patients with Systemic Lupus Erythematosus and Posterior Reversible Encephalopathy Syndrome: A Single-Center Study
Background/Purpose: Patients with systemic lupus erythematosus (SLE) are susceptible to the development of posterior reversible encephalopathy syndrome (PRES). The main theory about the physiopathology of…Abstract Number: 2950 • 2015 ACR/ARHP Annual Meeting
Using Electronic Health Record Algorithms to Accurately Identify Patients with Systemic Lupus Erythematosus
Background/Purpose: To harness the data in electronic health records (EHRs) and administrative databases to study systemic lupus erythematosus (SLE), it is important to identify patients…Abstract Number: 2951 • 2015 ACR/ARHP Annual Meeting
Anti-NR2 Antibody and Blood-Brain Barrier Disruption in Systemic Lupus Erythematosus Patients with Cognitive Dysfunction
Background/Purpose: Cognitive Dysfunction (CD) is one of the most common manifestations of neuropsychiatric SLE (NPSLE) and one of the most devastating. The pathogenesis of CD…Abstract Number: 2952 • 2015 ACR/ARHP Annual Meeting
Diagnosis of Primary Neuropsychiatric Systemic Lupus Erythematosus: Attribution Models Versus Physician Judgment
Background/Purpose: Attribution of neuropsychiatric manifestations to systemic lupus erythematosus per se (“primary NPSLE”) is challenging and depends largely on physician judgment based on clinical and…Abstract Number: 2953 • 2015 ACR/ARHP Annual Meeting
The Emergency Room and SLE: What Characteristics Are Associated with Increased Emergency Room Utilization in Lupus Patients?
Background/Purpose: There is sparse data examining the characteristics of SLE patients who frequent the emergency room (ER). Data suggest that lupus patients with certain sociodemographic…Abstract Number: 2954 • 2015 ACR/ARHP Annual Meeting
Serum and CSF Biomarkers of Neuropsychiatric Involvement in Primary Sjogren Syndrome and Systemic Lupus Erythematosus
Background/Purpose: Neuropsychiatric manifestations are commonly observed in both SLE and primary Sjšgren's syndrome (pSS). However, making an accurate diagnosis can be challenging. Multiple serum and…Abstract Number: 2955 • 2015 ACR/ARHP Annual Meeting
Cognitive Impairment in Lupus Patients: Identification of the Best Screening Test and Assessment for Associated Factors
Background/Purpose: There is an unmet need for a screening test of cognitive function that can be administered in clinic in patients with SLE. We…Abstract Number: 2956 • 2015 ACR/ARHP Annual Meeting
Patients’ Reported Perceived Deficits Questionnaire – 5-Item Is Not Valid to Screen for Cognitive Impairment in Lupus
Background/Purpose: It is unclear whether cognitive complaints in patients with SLE are indicative of true Cognitive Impairment (CI) or underlying depression or anxiety. To determine:…Abstract Number: 2957 • 2015 ACR/ARHP Annual Meeting
25-Hydroxyvitamin D3 Deficiency Independently Predicts Cognitive Impairment in Patients with Systemic Lupus Erythematosus: Results from a Controlled Study
Background/Purpose: Cognitive dysfunction has been reported in 20-80% of systemic lupus erythematosus (SLE) patients. Converging evidence has indicated the importance of vitamin D as a…Abstract Number: 2958 • 2015 ACR/ARHP Annual Meeting
Vitamin D, Cognition and Cerebral Structural Abnormalities in Childhood- Onset Systemic Lupus Erythematosus
Background/Purpose: About 16-95% of SLE patients have vitamin D insufficiency. Vitamin D levels, especially vitamin D deficiency, are associated with cognitive performance in adults. We…
